glp 1 heart disease GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms How GLP-1 Medications Reduce Heart

Access the Endocrinology Newsmakers Dashboard (Free Excel) Lillys Mounjaro, Novos Wegovy gear up for larger share of obesity pie In May 2022, Lillys potential blockbuster Mounjaro (tirzepatide) was approved by the US Food and Drug Administration (FDA) as a once-weekly subcutaneous injection to treat adults with type 2 diabetes

Patients with chronic gastrointestinal symptoms may also experience rapid weight loss, muscle wasting, fatigue, and worsening nutritional deficiencies over time

2019;68:1006P

only 43% of participants met the lower end of this g/kg/day recommendation

What Makes PlexusDx Medications Eligible for HSA/FSA Use PlexusDx compounds all GLP-1 medications through licensed 503A compounding pharmacies, which are FDA-regulated facilities that can customize formulations under a valid prescription

What's New with GLP-1 Coverage in 2026 While GLP-1 agonists have been around for over a decade now, they've seen a big jump in popularity in the last couple of years